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Abstract
High selectivities and exquisite control over reaction outcomes entice chemists to use biocatalysts 
in organic synthesis. However, many useful reactions are not accessible because they are not in 
nature’s known repertoire. We will use this review to outline an evolutionary approach to 
engineering enzymes to catalyze reactions not found in nature. We begin with examples of how 
nature has discovered new catalytic functions and how such evolutionary progressions have been 
recapitulated in the laboratory starting from extant enzymes. We then examine non-native enzyme 
activities that have been discovered and exploited for chemical synthesis, emphasizing reactions 
that do not have natural counterparts. The new functions have mechanistic parallels to the native 
reaction mechanisms that often manifest as catalytic promiscuity and the ability to convert from 
one function to the other with minimal mutation. We present examples of how non-natural 
activities have been improved by directed evolution, mimicking the process used by nature to 
create new catalysts. Examples of new enzyme functions include epoxide opening reactions with 
non-natural nucleophiles catalyzed by a laboratory-evolved halohydrin dehalogenase, 
cyclopropanation and other carbene transfer reactions catalyzed by cytochrome P450 variants, and 
non-natural modes of cyclization by a modified terpene synthase. Lastly, we describe discoveries 
of non-native catalytic functions that may provide future opportunities for expanding the enzyme 
universe.
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1. Introduction
Replete with nature’s solutions to catalyzing chemical transformations, our burgeoning 
genomic databases beautifully illustrate how evolution generates chemical innovation in the 
form of new enzymes. Today’s enormous biocatalytic diversity is the product of evolution 
from ancestral enzymes, the mechanisms of which are now being elucidated in 
unprecedented detail. Enzyme evolution is also alive and well and moving into the future: 
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new enzymes continue to appear in response to (often man-made) opportunities to survive 
challenges (e.g. antibiotic resistance) or occupy new niches (e.g. catabolize man-made 
compounds). Given nature’s ability to innovate, and our extremely limited ability to design 
new enzymes, we argue for using evolutionary strategies to create and tune enzymes fit for 
human applications.
Directed evolution is a powerful protein engineering approach that has been applied with 
great success for nearly two decades to fine-tune enzymes for chemical synthesis.1 A simple 
strategy of accumulating mutations via iterative mutagenesis and screening for desired 
functions can effectively optimize properties of interest—activity on non-native substrates, 
enantioselectivity, product selectivity, stability and more—and deftly circumvents our 
profound ignorance of how the enzyme sequence encodes these features. If chemists are to 
use enzymes in synthesis, these catalysts have to perform as well as or better than the 
alternatives. Often this is a high bar that no ‘rational design’ approach has been able to meet 
on a regular basis, but one where directed evolution performs well, given a good starting 
point.2 As a result, enzymes are increasingly used in chemical synthesis, where they offer 
significant advantages for ‘green’ processes3, production of chemicals from renewable 
resources,4 and synthesis of complex natural products.
Directed evolution can be used to diversify existing enzymes, creating variants that function 
in non-native environments, accept non-native substrates, or exhibit non-native selectivities. 
But how do we create whole new enzymes, including enzymes that catalyze reactions not 
known in nature? Nature’s catalyst reserve is vast and has not been fully mined; new 
enzymes will continue to be discovered. Chemists, however, are fond of a number of 
reactions for which there may well be no natural biocatalytic counterparts, either because 
nature has not discovered a need for them (our goals and requirements being different from 
those of a microbe or a tree) or because they require functional groups and reagents not 
normally found in the biological world. Our goal is to begin to address this gap between the 
enzymes we can find in nature and those we would like to have but may not exist. We 
believe we can use what we have learned of nature’s approach to inventing new catalysts in 
order to jumpstart the evolution of new enzyme families in the laboratory. We illustrate this 
evolutionary approach to catalyst discovery by starting with some examples from nature’s 
repertoire. In some cases, scientists have elucidated sequence and functional pathways that 
connect existing enzymes in order to demonstrate how natural evolution may have 
proceeded from one function to the other.
Can this knowledge help us step out into the unknown and create biocatalysts that have not 
yet been discovered in the natural world? That the answer is an emphatic “Yes!” is 
illustrated with several powerful examples of enzymes engineered to catalyze reactions with 
no known natural counterparts. We end by describing a few non-natural activities that might 
afford a peek into future enzyme families.
2. Nature’s Approach to Generating New Enzymes
Catalytic promiscuity refers to the ability of an enzyme to catalyze, in addition to its native 
function, reactions that target different functional groups on the substrate and proceed 
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through different transition states and/or reactive intermediates. In 1976, Jensen proposed 
that ancient enzymes were characterized by broad substrate and reaction scope and that 
natural selection picked up and fine-tuned these different activities to generate contemporary 
enzymes with specific catalytic functions (Figure 1A).5 But even today’s enzymes are not as 
specific as often thought—many can catalyze other transformations in their active sites and 
exhibit (usually low levels of) catalytic promiscuity.6 Much evidence now suggests that this 
often serendipitous catalytic promiscuity is in fact vital to the evolution of new enzymes, 
providing a platform for evolution of new functions by natural selection (Figure 1B).7
2.1. Evolution of atrazine chlorohydrolase (AtzA)
The evolution of atrazine chlorohydrolase (AtzA) is one of the best case studies of how 
nature exploits catalytic promiscuity to create new enzymes. A potent herbicide introduced 
in the late 1950s, atrazine was initially found to be minimally biodegradable. Since 1993, 
however, atrazine has been observed to be degraded rapidly by soil microbes in diverse 
locales, a phenomenon attributed to the presence of the enzyme AtzA.9 This enzyme 
catalyzes the hydrolysis of the C-Cl bond of atrazine (Figure 2A) through a nucleophilic 
aromatic substitution reaction with a Fe2+-activated water molecule.
The amino acid sequence of AtzA from Pseudomonas sp. ADP is 98% identical to that of 
melamine deaminase (TriA), an enzyme originally isolated from Pseudomonas sp. strain 
NRRL B-12227. TriA catalyzes the hydrolysis of the C-N bond of melamine, another non-
natural compound that was originally classified as non-biodegradable in the 1930s, but was 
slightly degradable by the time atrazine was first introduced.10 The two enzymes differ at 
only nine out of 475 amino acids.11 This extremely high level of identity and the fact that 
both enzymes can be found in at least one common bacterial species suggested that AtzA 
evolved from TriA or from a common ancestral enzyme similar to TriA (Figure 2B), 
enabling the bacteria to capitalize on a new opportunity to use these synthetic compounds as 
nitrogen sources.12
Progression from melamine to triazine degradation represents evolution of a new catalytic 
function, from C-N bond cleavage (aminohydrolase, EC 3.5.4) to C-Cl cleavage 
(chlorohydrolyase, EC 3.8). Although other chlorohydrolases exist in nature, they typically 
use a carboxylate nucleophile instead of water activated by a divalent metal, as found for 
AtzA. In contrast, enzymes in the aminohydrolase (e.g. TriA) family typically utilize a 
divalent metal such as Zn2+ cation to activate water for nucleophilic aromatic substitution. 
The active site similarity between TriA and AtzA, as suggested by homology modeling, 
further corroborates the conjecture that AtzA evolved from an ancestral aminohydrolase 
(Figure 2B).
TriA and AtzA differ at 9 positions, but Scott and co-workers recently showed that two 
mutations are sufficient to convert TriA to an enzyme with atrazine chlorohydrolase activity 
comparable to AtzA.13 Cys331Ser and Asp328Asn, mutations suggested by homology 
modeling to lie in the active site, improve the kcat/KM for atrazine hydrolysis dramatically, 
from 60 M−1s−1 to close to 10,000 M−1s−1, while completely abolishing melamine 
hydrolysis activity. Furthermore, Scott and co-workers showed that one can arrive at an 
atrazine chlorohydrolase by accumulating single beneficial mutations in a simple uphill 
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walk, starting from TriA. The Cys331Ser mutation alone improved the kcat/KM for atrazine 
hydrolysis by almost 30-fold. Introduction of Asp328Asn to the Cys331Ser mutant 
conferred a further six-fold improvement in catalytic efficiency.
These active site mutations effect a dramatic shift from aminohydrolase to chlorohydrolase 
activity that can be rationalized after the fact. Scott and coworkers reasoned that the Asn/Ser 
dyad (positions 328 and 331 in AtzA) assists in the expulsion of chloride anion through a 
hydrogen bonding network, whereas the Asp/Cys dyad in TriA enables the release of 
ammonia through a proton relay mechanism whereby the thiol moiety of Cys331 donates a 
proton to the leaving NH2− group and is reprotonated by Asp328. Since NH2− is a poor 
leaving group (pKa = 34), protonation by the more acidic Cys residue is necessary for the 
reaction to occur.
A number of functionally diverse enzyme superfamilies have been described.14 Superfamily 
members share a structural fold and are believed to have diverged functionally from a 
common ancestor through a series of catalytically promiscuous intermediates. Most known 
member enzymes that catalyze different reactions, however, have accumulated many more 
sequence changes than the AtzA/TriA pair; large sequence distances make it more 
challenging to demonstrate simple evolutionary pathways among them or to pinpoint the 
functions of the ancestral enzymes. But several research groups have taken on this 
challenge, using protein engineering and especially directed evolution to demonstrate how 
one function can become another in the context of extant enzymes.
2.2. Evolution of a phosphotriesterase (PTE)
Another enzyme believed to have emerged very recently is phosphotriesterase (PTE), first 
identified in soil bacteria that can grow on synthetic organophosphate pesticides such as 
parathion and paraoxon as its sole phosphorus source (Figure 3A).15 Given the recent 
introduction of parathion and paraoxon into the environment and the fact that PTE 
hydrolyzes them at near diffusion-controlled rates, it is thought that PTE evolved recently 
from an ancestral enzyme having promiscuous organophosphate hydrolysis activity. The 
ancestral enzyme is unknown, however, as no very close sequence homolog has been 
identified.
The PTE from P. diminuta has the (β/α)8-barrel fold and binuclear metal center common to 
many members of the amidohydrolase (AHS) superfamily that hydrolyze different classes of 
substrates.16 Afriat et al. proposed that this PTE’s promiscuous lactonase activity could be a 
vestige of its ancestral source, a clue to its ancestral function.17 They showed that three 
microbial enzymes that are the closest known homologs to P. diminuta PTE (~30% 
sequence identity) are in fact highly active lactonases and also possess varying levels of 
promiscuous organophosphate hydrolysis activity. These ‘phosphotriesterase-like 
lactonases’ (PLLs) are especially active towards N-acyl homoserine lactones, which play a 
vital role in bacterial quorum sensing.18 Afriat et al. argued that PTE may have evolved 
from the weak promiscuous activity of a bacterial PLL.
Raushel and co-workers recently conducted an experiment to try to recapitulate the 
conversion of a PLL with low-level organophosphate-degrading activity to a PTE.19 Using a 
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combination of rational and random mutagenesis, they were able to convert the PLL from 
Deinococcus radiodurans (DrPLL) to an enzyme exhibiting PTE activity that is five orders 
of magnitude higher than the wild-type DrPLL and just one order of magnitude lower than 
wild-type PTE. The most efficient enzyme contained only seven mutations from wild-type 
DrPLL, three of which were sufficient to increase the PTE activity by two orders of 
magnitude. Tawfik and co-workers showed that the converse is also possible when they 
engineered a recombinant variant of PTE from P. diminuta to be a bifunctional PTE/PLL by 
active-site loop remodeling.20
Similar to AtzA, PTE is believed to have arisen in response to the introduction of synthetic 
compounds that are potential new nutrient sources (Figure 3B). Unlike AtzA and TriA, 
however, PTE has low sequence identity to its closest known homolog, which is thought to 
be a lactonase. Despite the fact that the known PTE and PLL enzymes differ at hundreds of 
amino acid positions and in the structure and arrangement of the active site loops through 
deletions and/or insertions, their functions overlap and could be interconverted by directed 
evolution and rational design. That this could be done in the laboratory demonstrates the 
ease with which a promiscuous PLL could become a PTE in nature.19 This example also 
demonstrates how readily a residual ancestral activity can be enhanced by accumulating 
beneficial mutations.
2.3. Catalytic promiscuity in the MBL superfamily
In a comprehensive study of how catalytic functions overlap in the metallo-β-lactamase 
(MBL) superfamily of αβ/βα proteins, Tokuriki and co-workers examined the activities of 
24 enzymes from 15 distinct subfamilies.21 They found that many MBL superfamily 
members, despite their low sequence identities (ca. 5–35%), catalyze at low levels the 
distinct reactions of distant family members in addition to their own (Figure 4). Echoing a 
common theme in enzyme evolution that active site architecture within a superfamily is 
often at least partially conserved,22 most members of this superfamily retain the binuclear 
active-site center for divalent metal activation of a water molecule. Thus, observed 
promiscuous activities are likely to arise from the shared active site features of the 
superfamily members. The MBL superfamily also includes a PTE family that likely evolved 
from lactonases, in parallel with the PTEs in the AHS superfamily and in what appears to be 
an example of convergent evolution of a new function.23
Figure 4 illustrates the highly interconnected network of overlapping functions that Tokuriki 
and co-workers sampled in this superfamily. These enzymes presumably evolved from a 
common ancestor through a series of promiscuous intermediates. Promiscuity is still 
prevalent in the family, and given the level of functional overlap that still exists it is 
reasonable to assume that one could move within this network from one catalytic function to 
others by directed evolution. In fact, Park et al. showed the feasibility of converting a 
glyoxalase II from this family to an enzyme with high β-lactamase activity using directed 
evolution.24
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2.4. Evolution of a hydroxylase from a desaturase
Oleate desaturases and hydroxylases are integral membrane di-iron enzymes (Figure 5A) 
that catalyze the modification of oleic acid (1) to make the corresponding dehydrogenated 
and oxygenated products, linoleic acid (2) and ricinoleic acid (3). They typically exist in 
higher plants and are closely related members of a functionally diverse non-heme di-iron 
enzyme family. The two reactions are also mechanistically related in that they are both 
initiated by a hydrogen abstraction step.25 They diverge in the subsequent step, where 
desaturation occurs via another hydrogen abstraction and hydroxylation proceeds through a 
radical rebound/oxygen transfer event.
When expressed in yeast, the hydroxylase from L. fendleri, LFAH12, was found to have 
appreciable desaturase activity in addition to its native hydroxylase activity (producing ca. 
1:1 di-unsaturated fatty acids:hydroxylated fatty acid).26,27 In contrast, the desaturase from 
A. thaliana, FAD2, was shown to catalyze desaturation almost exclusively, with only very 
minor hydroxylation products detected (hydroxylation:desaturation product ratio of 0.006). 
These two enzymes are close relatives, with ~81% sequence identity, and a sequence 
comparison of the two with a few other hydroxylases and desaturases led to the 
identification of several residues that are highly conserved in the desaturases but diverged in 
the hydroxylases.26 Based on this, seven residues from FAD2 were introduced into the 
corresponding positions in LFAH12. The resulting variant showed predominantly desaturase 
activity, and further mutation analysis demonstrated that as few as six mutations could 
transform LFAH12 into a desaturase (Figure 5B). Conversely, four mutations were found 
sufficient to convert FAD2 into a hydroxylase. Further studies by Broadwater et al.27 
showed that a single mutation was sufficient to achieve a comparable boost in hydroxylase 
activity in FAD2.
This desaturase-hydroxylase example demonstrates how easily related enzymes with 
overlapping activities can be interconverted, similar to what was observed for the atrazine 
chlorohydrolase and phosphotriesterase examples. It was not necessary to identify and enlist 
the ancestral enzyme for evolution of the new functions—the new enzymes were obtained in 
the laboratory starting from the extant relative. And, as these examples suggest, a few 
mutations can be sufficient to convert an existing enzyme to a new one with distinct, but 
mechanistically-related activity. 22
We have chosen just a few examples to illustrate how enzymes catalyzing different reactions 
can diverge from a common ancestor, especially when the activities overlap at least a little. 
Nature does it, and the laboratory experiments demonstrate just how easily it can happen. 
Although nature may not have taken the same routes or starting points, the laboratory 
experiments show how a new enzyme can appear and evolve as opportunities for a selective 
advantage arise. Now let us discuss using this strategy to make enzymes that catalyze 
reactions not already discovered in nature.
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3. Using Mechanistic Similarities and Directed Evolution to Expand the 
Enzyme Universe
Many contemporary enzymes have versatile active sites and exhibit promiscuous activities 
at some level as a property of their mechanisms.28 Thus, as the above examples show, 
related enzymes that diverged by natural evolution for different functions can be 
interconverted and optimized, often with just a few mutations in an uphill evolutionary walk. 
Because catalytic promiscuity is common, today’s plethora of biocatalysts provides equal or 
perhaps even greater opportunities for innovation than in early evolution. Just as nature uses 
that rich source of starting materials to create new catalysts, so could we.
Let us suppose for a moment that an atrazine chlorohydrolase had not yet been discovered in 
nature. Could its appearance have been anticipated, and could such an enzyme have been 
created in the laboratory before it was found in nature? Given the similarity in substrate 
structure (s-triazine heterocyclic core) and reaction type (hydrolysis), one might logically 
test an aminohydrolase such as TriA as a starting point for directed evolution. As atrazine 
contains a better leaving group (Cl− versus NH2−), its hydrolysis could be expected to be 
more facile than melamine. Indeed, TriA possesses a low level of atrazine chlorohydrolase 
activity (kcat/KM = 60 s−1M−1). From there, one could couple random or site-saturation 
mutagenesis with a high-throughput spectrometric assay29 for the hydrolysis product to 
identify variants with increasing levels of activity. As Scott and co-workers showed, 
accumulating just two mutations improved the chlorohydrolase activity of TriA almost 200-
fold.13
Given that a new, mechanistically-related catalytic function can be imparted with just a few 
mutations to an enzyme that already possesses a low level of that function, an evolution-
inspired approach to new catalyst discovery relies on being able to identify an appropriate 
starting point, that is, an existing enzyme able to take on a new function. To find that 
enzyme, we can look for mechanistic similarities between an existing activity and a desired 
transformation for which no enzyme is known. And, because low levels of catalytic activity 
exhibited by a promiscuous enzyme can be improved in many cases by engineering the 
protein sequence, there is the reasonable expectation that a non-natural, but mechanistically-
related promiscuous activity can similarly improve.
In fact, several laboratories have used this approach and capitalized on the catalytic 
promiscuity of enzymes and the similarity between the native and desired reaction 
mechanisms in order to create new enzymes. In some cases, however, the starting enzyme 
did not exhibit the desired promiscuous activity, and researchers had to rely on their 
chemical intuition that the desired function should be possible and could be obtained with 
one or a few mutations. In this section, we will present some examples of novel non-natural 
functions that have been discovered using this mechanism-based approach and then 
improved to useful levels by protein engineering and especially directed evolution.
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3.1. Epoxide ring opening with a halohydrin dehalogenase
Wild-type halohydrin dehalogenases (HHDH) catalyze the formation of epoxides from the 
corresponding chloro- and bromohydrins.30 X-ray structures of halohydrin dehalogenase 
from Agrobacterium radiobacter AD1 suggested the presence of a binding site for both the 
epoxide and halide anion,31 thus raising the possibility of using pseudohalides of varying 
sizes in the reverse epoxide opening reaction. Indeed, Janssen and coworkers found that this 
enzyme accepts a wide range of non-natural nucleophiles such as azide, nitrite, cyanate and 
thiocyanate32 and used it for kinetic resolution of various epoxides to give the ring-opened 
products with high enantioselectivity (Figure 6A). In addition, high selectivity for opening at 
the terminal position was observed. In the case of aryl epoxide substrates, this finding stood 
in stark contrast to the non-catalyzed ring opening reaction, where nucleophilic attack 
usually occurs at the benzylic position.
In 2007, scientists at Codexis reported the use of HHDH in the asymmetric synthesis of 
ethyl (R)-4-cyano-3-hydroxybutyrate (6),33 a valuable intermediate in the production of 
atorvastatin, a cholesterol-lowering drug. They were able to enhance the low activity of the 
wild-type enzyme for the cyanation of 5 by directed evolution to obtain enzyme variants that 
increased the volumetric productivity of the process by ~4000-fold (Figure 6B).34 This 
catalyst enables production of 6 at >99.9%ee with a substrate loading of 130 g/L.
The promiscuous cyanation activity of HHDH was discovered through a combination of 
enzyme structure analysis and analogy to related chemistry of epoxide ring-opening with 
non-natural pseudohalide nucleophiles. The low cyanation activity of wild-type HHDH 
could then be improved tremendously by directed evolution, accumulating beneficial 
mutations in an uphill walk to the new function.
3.2. Synthesis of S-oligosaccharides with an engineered glycosidase
A good strategy for introducing a new activity can be to divert a reactive intermediate to an 
alternative reaction pathway, as nature did with the hydroxylase and desaturase enzymes. A 
nice example comes from early work of Withers. By examining the catalytic strategy of 
retaining β-glycosidases and rationally modifying the key catalytic residue(s), Withers and 
co-workers were able to divert a reactive intermediate in the hydrolysis of glycosidic bonds 
and redirect it to synthesis of S-oligosaccharides.35
S-oligosaccharides are of interest as carbohydrate mimics that possess a more stable and 
hydrolysis-resistant glycosidic bond.36 These compounds are challenging to synthesize, 
because their preparation typically involves manipulation of protecting groups and requires a 
high degree of stereocontrol at the anomeric position. A few enzymes are known that 
catalyze the formation of the C-S bond of naturally-occurring thioglycosides, but there are 
only very few reports of their use in the preparation of S-oligosaccharides.37
Glycosidases catalyze the hydrolytic cleavage of glycosidic bonds and are mainly 
responsible for the degradation of carbohydrate-based biomass. In low water concentration, 
these enzymes are also capable of catalyzing glycoside exchange. For retaining β-
glycosidases, the enzymatic hydrolysis and glycoside exchange reaction occurs through a 
double substitution mechanism where a catalytic nucleophile residue first displaces the 
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departing aglycon group and a catalytic acid/base residue activates the incoming water or 
glycoside nucleophile to form the new anomeric bond (Figure 7A).38
To create a new activity, it is helpful if the starting enzyme already exhibits it at some level 
as a promiscuous activity, but this is not necessarily required. In such a case, however, the 
catalytic mechanism must allow acquisition of the new activity without too much fine-
tuning. By substituting the catalytic acid/base glutamine residue with an inert alanine 
(Figure 7B), Withers and co-workers re-designed the active site of β-glucosidase from 
Agrobacterium sp. (Abg) and β-mannosidase (Man2A) from Cellulomonas fimi such that 
they would only catalyze the glycosylation of activated dinitrophenyl (DNP) glycoside 
donors and deoxythio sugars as acceptors. The former does not require acid activation since 
it is a good enough leaving group to be displaced by the catalytic nucleophile residue, and 
the latter contains a highly nucleophilic thiol moiety that does not require base catalysis for 
the formation of the glycosidic linkage.
Both glycosidase mutants were shown to catalyze the reaction of DNP glucose and DNP 
mannose with glycoside acceptors 7 and 8 in good to excellent yields (Figure 8). Notably, no 
protecting groups were required on the free hydroxyl groups of the glycoside donors and 
acceptors. In further work, Withers and co-workers showed that mutations at the catalytic 
acid/base residue could boost the thioglycoligase activities of these retaining β-
glycosidases.39
3.3. Carbene and nitrene transfer reactions with cytochrome P450s
Metalloporphyrin complexes, long used as synthetic models for cytochrome P450 enzymes, 
also catalyze chemical reactions that have no natural counterparts. For example, the reaction 
of metalloporphyrins, including iron porphyrins, and diazo compounds to generate 
metallocarbenoid reactive intermediates for cyclopropanation reactions is well-documented 
in the synthetic literature (Figure 9A).40 Whereas carbenes are generally too reactive for 
characterization, some of these metallocarbenoid species proved to be stable enough for 
isolation and X-ray crystallography analysis.41 These isolated metallocarbenoids participate 
in cyclopropanation reactions, providing evidence that metalloporphyrin-catalyzed 
cyclopropanations proceed through the metallocarbenoid intermediates.
Metalloporphyrins are also known to form reactive nitrenoids in the presence of activated 
species such as azides and iminoiodinanes. Breslow and Gellman first showed that meso-
tetraphenylporphyrin iron(III) chloride could catalyze intra- and intermolecular nitrene 
transfer when reacted with iminoiodinanes,42 presumably via a metallonitrenoid species. A 
follow-up report by Dawson and co-workers further established that a rabbit liver 
cytochrome P450 could catalyze the same nitrene transfer reaction, albeit in very low 
turnover.43 Given the similarity between carbene/nitrene and oxene–the reactive species in 
P450 monooxygenation reactions–in electronic configuration and thus reactivity (Figure 
9B), our laboratory hypothesized that cytochrome P450s may exhibit promiscuous activity 
for carbene and nitrene transfer reactions and that such activities could be improved by 
protein engineering. Addition of ethyl diazoacetate to styrene in the presence of wild-type 
P450-BM3 from B. megaterium led to trace amounts of the corresponding cyclopropane 
product.44 Further work established that various hemeproteins, and even free hemin, 
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catalyze olefin cyclopropanation in water.45 Of particular interest, however, several wild-
type P450s exhibited diastereoselectivity different from free hemin and showed some 
enantioinduction as well.44,45 The unusual selectivity of the P450s suggested that 
cyclopropanation was taking place in the enzyme active site and that the active site 
geometry exercised control over the stereochemical outcome of the reaction. We thus felt 
that the P450s were suitable starting points for engineering and evolution of a new family of 
enzymes that can activate diazo compounds for carbenoid transfers to organic 
molecules.44,46–50
Mutations dramatically increase the non-natural cyclopropanation activity of P450-BM3. 
Substitution of the distal threonine (Thr268), a key residue in the native catalytic cycle for 
monooxygenation, with alanine improved the turnover number more than 60-fold. Further 
tailoring of the active site led to variant P450BM3-CIS-T438S that catalyzed the 
cyclopropanation of styrene in excellent yield, diastereoselectivity, and enantioselectivity 
(Figure 10A). Mutation at the cysteine axial ligand led to the greatest improvement in 
cyclopropanation activity. Mutating the cysteine at position 400 to serine (Cys400Ser) in 
P450-BM3 shifted the characteristic 450 nm peak in CO-difference spectrum to 411 nm, 
hence the “P411” name for the Ser-ligated catalysts. The Ser mutation also allowed the iron 
heme to be reduced under cellular conditions to the Fe2+ active catalyst, thereby enabling 
cyclopropanation with whole cells expressing these proteins. Styrene cyclopropanation was 
catalyzed on gram scale to 67,000 turnovers in 72% yield by a P411, which is competitive 
with some of the most active reported rhodium catalysts. 46
Enzyme-catalyzed cyclopropanation has been applied to the formal synthesis of 
levomilnacipran, a serotonin and norepinephrine reuptake inhibitor approved for the 
treatment of clinical depression.47 A variant of P450-BM3 containing only five amino acid 
mutations, including mutation of the proximal cysteine residue to histidine, catalyzed the 
cyclopropanation of N,N-diethyl-2-phenylacrylamide (13) to 86% yield and 92% 
enantioselectivity on preparative scale (Figure 10B). The laboratory-evolved catalyst BM3-
Hstar performed cyclopropanation in the presence of oxygen and exhibited an initial rate of 
reaction close to what has been reported for monooxygenation by wild-type P450-BM3 
(>1000 turnovers per minute). Examination of a panel of 2-phenylacrylamide derivatives 
revealed that BM3-Hstar was quite a general cyclopropanation catalyst and could be used on 
substrates with varied steric and electronic properties.48
Carbene insertion into aryl N-H bonds, another reaction catalyzed by iron porphyrins, can 
also be catalyzed by variants of P450-BM3. 49 P411 variant H2-5-F10 performed the 
insertion into aryl N-H bonds in up to 83% yield and 354 turnovers in vitro (Figure 10C). 
Free Fe-protoporphyrin IX can catalyze aniline N-H insertion reactions, producing a mixture 
of single and double insertion products. In contrast, the enzyme provided the single insertion 
product selectively, highlighting the important role that the protein binding pocket plays in 
controlling selectivity.
Following up on the early observation of Dawson and coworkers,43 McIntosh et al. greatly 
improved the catalytic performance of P450-BM3 for intramolecular C-H amination with 
sulfonyl azides as the nitrene precursor.50a For azide 15, mutations at key residues such as 
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Thr268 on the I helix (Thr268Ala) and the cysteine proximal ligand for the heme prosthetic 
group (Cys400Ser) were found to be crucial for improving the total turnover number for 
amination (Figure 10D). In particular, variant P411BM3-CIS catalyzed the amination 
reaction in up to 87% enantioselectivity and 430 turnovers. The same variant was also found 
to catalyze nitrene transfer from p-toluenesulfonyl azide to a series of thioethers to generate 
the corresponding sulfimides in 30–300 turnovers (Figure 10E).50b Since free hemin does 
not catalyze this sulfimidation reaction at all, the ligation state of the heme cofactor in the 
protein and/or the protein itself play a key role in modulating the reactivity of the nitrenoid 
species.
An independent report by Fasan and co-workers revealed that intramolecular C-H amination 
of sulfonyl azide 16 could be effected by a different variant of P450-BM3 (FL#62) that does 
not contain the Thr268Ala and Cys400Ser mutations.51a Their investigation of the substrate 
scope of intramolecular C-H amination with FL#62 showed that the biocatalyst tolerates a 
range of substituents on the aryl ring. A follow-up report51b further showed that C-H 
amination on azide 16 could be catalyzed in good turnovers using either myoglobin (Mb) or 
horseradish peroxidase (HRP). Whereas wild-type Mb showed no detectable 
enantioselectivity in amination with 16, introduction of mutations His64Val and Val68Ala 
led to appreciable enantioinduction (60% ee with 16). These results suggest that other 
hemoproteins are also viable platforms for discovering new catalysts for non-natural 
reactions.
Hyster et al. very recently showed that the regioselectivity of this enzyme-catalyzed C-H 
amination can be tuned by mutations (Figure 10F).50c Variant P411BM3-CIS-T438S-I263F 
catalyzed C-H amination of substrates 17a–c at the homo-benzylic position with excellent 
regio- and enantioselectivity. The P411BM3-T268A-F87A variant, in contrast, showed strong 
preference for C-H amination at the benzylic position, also with great regio- and 
enantioselectivity. Thus tailoring the active site can alter the conformation of the reactive 
intermediates to the extent that the catalyst can override the thermodynamic bias towards 
reaction at the benzylic position (the bond dissociation energy for the benzylic C-H is 
weaker by more than 10 kcal/mol relative to non-benzylic C-H).
3.4. Redirecting cyclization with terpene synthases
Squalene-hopene cyclase (SHC) catalyzes the cationic polycyclization of squalene to the 
pentacyclic products hopene and hopanol (Figure 11), a reaction that Hauer and co-workers 
noted is highly reminiscent of chiral Brønsted acid-catalyzed polycyclizations.52 The crystal 
structure of SHC from Alicyclobacillus acidocaldarius (AacSHC) was disclosed in 1997,53 
but its promiscuity was known as early as 1986, when Neuman et al. showed that 
homofarnesol could be cyclized by SHC to ambroxan, a valuable fragrance compound.54 
This reaction can be regarded as both a substrate and catalytic promiscuity feature of the 
enzyme, because attack by an internal nucleophile terminates the cyclization reaction.
Hauer and co-workers further investigated the inherent promiscuity of this enzyme with a 
range of terpene-like substrates to construct novel carbocyclic skeletons (Figure 12A). By 
varying the terminator groups for the cyclization reactions, they were able to perform SHC-
catalyzed cyclization of various non-natural substrates in low to moderate yield.54,55 The 
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substrate scope for SHC-catalyzed cyclization reaction has also been studied by Hoshino 
and co-workers.56
SHC also possesses some weak activity for Prins cyclization of citronellal to form 
isopulegol.57 Siedenburg et al. conducted site-saturation mutagenesis on three residues in 
the active site of SHC from Z. mobilis (ZMO1548) to improve production of isomers of 
isopulegol starting from racemic citronellal (Figure 12B).58 Two amino acid positions were 
identified as important for increased isopulegol formation. The Trp555Tyr mutant gave 
more than 70% total conversion to isomeric mixtures of isopulegol, versus ca. 30% observed 
with the wild-type enzyme. The Phe486Cys variant provided more than 50% total 
conversion, with slightly improved product diastereoselectivity.
In a very recent study,59 Hauer and co-workers engineered an SHC from A. acidocaldarius 
(AacSHC) to improve the catalytic activity for several different modes of Brønsted acid-
catalyzed cyclizations, including the Prins cyclization of (S)-citronellal (Figure 13). 
Screening a library of enzyme variants made by mutating several amino acids in proximity 
to the catalytic Asp376 residue, they discovered variants with greatly improved activities for 
various cyclization reactions. The Tyr420Trp-Gly600Phe mutant catalyzed the cyclization 
of 6,7-epoxygeraniol to cyclohexanoid 22 in 78% conversion, an approximately 140-fold 
improvement over the wild-type enzyme. Similarly, the Ile261Ala mutant catalyzed the 
Prins cyclization of (S)-citronellal to iso-isopulegol in 11% conversion, an approximately 
20-fold improvement over the wild-type enzyme. It will be interesting to see if this non-
natural cyclization activity of SHC or other terpene synthases can be expanded further to 
include other electrophiles as initiators.60
4. New Opportunities on the Horizon?
At present, biocatalytic transformations constitute a small but growing subset of industrially 
relevant chemical processes. In order to fully realize the potential of biocatalysis for 
sustainable chemistry, it will be important to expand the range of enzyme-catalyzed 
transformations to include ones not yet discovered in nature. The examples we have 
presented illustrate an evolutionary approach that mimics some features of how nature 
creates new catalysts. Our feeling is that we have barely scratched the surface of 
possibilities, as promiscuous activity among enzymes is widespread and can be improved by 
protein engineering and especially directed evolution. Chemical intuition will help us know 
where to look for new opportunities.
Several recent discoveries of novel, promiscuous, and non-natural enzyme activities 
highlight the potential for future biocatalyst development. Still in their infancy, these next 
examples are important proofs-of-concept with potential for future applications. Where 
wild-type enzymes catalyze non-natural reactions, it is entirely possible that protein 
engineering and directed evolution could boost activity, fine-tune selectivity, and make them 
more synthetically useful.
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4.1. C-H functionalization chemistry of SyrB2 halogenase
Reminiscent of the hydroxylase/desaturase example, nature utilized a similar bifurcation of 
reaction pathways for halogenation and hydroxylation with Fe(II)- and α-ketoglutarate-
dependent (Fe/αKG) enzymes. An Fe/αKG enzyme from the syringomycin biosynthetic 
pathway of Pseudomonas syringae B301D, SyrB2 catalyzes the halogenation of the terminal 
methyl group of L-threonine appended to the carrier protein SyrB1.61 This enzyme is related 
to Fe/αKG hydroxylases which employ an almost identical reaction mechanism. Both 
reactions proceed via an initial hydrogen atom abstraction from the substrate by an Fe(IV)-
oxo intermediate to form a carbon-centered radical (Figure 14).62 The subsequent step 
determines the product outcome: homolytic coupling with a hydroxyl ligand results in the 
hydroxylated product (path a) whereas coupling with a halogen ligand results in chlorinated 
or brominated product (path b). One fundamental difference between the two enzymes lies 
in the presence of a coordinating Asp/Glu residue in Fe/αKG hydroxylases whereas a non-
coordinating Ala occupies this position in SyrB2 halogenase. As a result, the Fe center in the 
latter has an additional coordination site, which is occupied by a halide anion that is 
eventually incorporated in the product. Given such similarities in structure and mechanism, 
Walsh and coworkers proposed that Fe/αKG halogenase evolved from Fe/αKG 
hydroxylase.63
Using threonine as substrate, SyrB2 is remarkably selective for the production of 4-chloro-
L-threonine, suggesting that hydroxyl radical rebound from intermediate A (Figure 14A) is 
not competitive with halogen radical rebound. Substitution of the non-coordinating Ala with 
Glu in SyrB2 led to the formation of a hydroxylase-like metal center, but this mutant was 
shown to be an inefficient hydroxylase.64 Furthermore, the use of norvaline, a five-carbon 
amino acid, as a substrate for wild-type SyrB2 led almost exclusively to the hydroxylation 
product (Figure 14B). These results suggest that a complex interplay between substrate and 
protein active site determines the selectivity between hydroxylation and halogenation. To 
further reinforce this notion, simple substitution of coordinating Asp to Ala on prolyl 4-
hydroxylase, an Fe/αKG enzyme, led to an inactive enzyme.65 Thus, despite the presumed 
evolutionary relationship between the two enzymes, the simplistic notion of creating a 
vacant coordination site for halide binding to convert a hydroxylase to halogenase only 
works in very special cases.
Many Fe/αKG hydroxylases have been discovered that act on different types of substrates, 
and some of them do not require the substrates to be appended to a carrier protein. Fe/αKG 
halogenases, however, are relatively rare in nature. Conversion of hydroxylases to 
halogenases would allow rapid diversification of secondary metabolites produced by 
Fe/αKG enzymes. These metabolites include valuable β-lactam antibiotics and modified 
amino acids and nucleobases.66
The chemistry of SyrB2 can also be diversified to include non-natural functions. Matthews 
et al. recently demonstrated that in the presence of N3− or NO2− wild-type SyrB2 could 
catalyze radical azidation and nitration of substrates (L-2-aminobutyrate, L-threonine, and 
L-norvaline) bound to SyrB1 with modest yields under single turnover conditions.67 Such 
reactivity is reminiscent of radical-based C-N coupling in synthetic chemistry, where 
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literature precedents suggest that many nitrogen-containing species such as azides and nitrite 
salts are viable partners in radical coupling reactions.68 At this point, however, the enzyme-
catalyzed reaction requires that the substrates be appended to the carrier protein and gives 
modest yields even under single turnover conditions. In addition, given the apparent 
complexity of substrate positioning in the active site in determining the outcome of Fe/αKG-
catalyzed reactions, optimization of these new nitration and azidation reactions may be 
challenging.
4.2. Unnatural amino acid synthesis with O-acetylserine sulfhydrylase and tryptophan 
synthase
Natural and unnatural amino acids are important constituents of many active pharmaceutical 
ingredients (APIs); it has been estimated that they comprise 18% of the building blocks used 
in the pharmaceutical and agrochemical industries.69 Natural L-amino acids are produced 
mainly via fermentation and extraction from raw feedstocks. Unnatural amino acids 
(UAAs), however, are commonly produced by chemical synthesis, as there exists no 
biosynthetic pathway for the introduction of unnatural side chains. Numerous synthetic 
methods have been developed for the synthesis of UAAs, but commercial production 
typically relies on asymmetric hydrogenation or resolution of racemic mixtures.70 These 
processes often require manipulation of protecting groups (that have to be removed) and 
catalysts that have to be designed de novo for new targets. Development of biosynthetic 
pathways for UAAs could potentially streamline their production.
O-acetylserine sulfhydrylase (OASS, this term is used interchangeably with cysteine 
synthase) is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the final step of 
cysteine biosynthesis.71 After aldimine formation between O-acetylserine and PLP, the 
acetate group of O-acetylserine is extruded to give an amino acrylate intermediate which 
then reacts with H2S to form L-cysteine (Figure 15). In the late sixties, Mudd and Thompson 
independently established72 that this class of enzymes also catalyzed the synthesis of S-
substituted cysteine derivatives, hinting at relaxed substrate specificity of these enzymes. 
Although rare, heterocyclic β-substituted alanines do occur naturally in plants.73 Elucidation 
of the biosynthetic pathways of these non-proteinogenic amino acids showed that they arose 
from the condensation of O-acetyl-L-serine with the appropriate nucleophiles.
Hypothesizing that this pathway shares a common reactive intermediate and reaction 
mechanism with OASS, Ikegami and co-workers in a series of publications showed that the 
OASS from higher plants could indeed catalyze the syntheses of β-(pyrazol-1-yl)-L-alanine, 
L-quisqualic acid, L-mimosine and several other non-proteinogenic amino acids in low 
yields.74 As Maier showed in a follow-up work,75 the overall metabolic pathway could be 
engineered to improve the low titers. However, no report has disclosed improving the 
production yield of UAAs by engineering the OASS enzyme. X-ray structures of CysK1 and 
CysM, both cysteine synthases, indicated the presence of a substrate tunnel that likely acts 
as a passageway for incoming nucleophiles.76 Engineering this substrate tunnel to 
accommodate nucleophiles of different size could provide an alternative avenue to improve 
the production of UAAs.
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Tryptophan synthase catalyzes the formation of tryptophan through a mechanism that bears 
a strong resemblance to that of OASS. In the β subunit of the enzyme, condensation of 
serine with PLP is followed by a dehydration to afford an aminoacrylate intermediate which 
then undergoes a conjugate addition with indole.77 Just like OASS, tryptophan synthase 
possesses a hydrophobic tunnel for the passage of indole. The wild-type enzyme has been 
shown to catalyze the production of various tryptophan analogs through the use of the 
corresponding heterocyclic nucleophiles such as thienopyrroles, azaindoles and indazole 
(Figure 16).78 At present, however, optimization of this enzyme is still required to make the 
process practical. As with OASS, directed evolution and protein engineering efforts could 
render this enzyme more useful for the production of UAAs.
5. Conclusions
Over the last fifty years, chemists have invented creative synthetic disconnections that are 
not found in nature. We believe that at least some of these reactions could be imported into 
biological systems. The challenge for engineering enzymes to catalyze non-natural 
chemistry is that there is not another enzyme to provide the inspiration or guide the 
engineering—that leap has to come from luck (accidental discovery of an interesting 
promiscuous activity), laborious screening of enzymes for non-natural functions, or, better, 
from chemical intuition/design based on known synthetic transformations. The carbenoid 
and nitrenoid transfer reactions catalyzed by engineered cytochrome P450s are a good 
example of how new enzymes can be generated using an approach that mimics nature and is 
based on chemical knowledge: work with transition metal catalysts and mechanistic 
similarities provided the inspiration, the promiscuity of the natural P450 enzymes provided a 
starting point, and protein engineering/evolution provided the means to tune reactivity and 
selectivity. Similarly, the various synthetic methods developed for C-N coupling (for which 
there is no natural counterpart) served as a motivation to investigate an enzymatic equivalent 
in SyrB2 halogenase.
But can every poorly active enzyme be engineered or evolved for high activity? This is 
clearly not the case. If it were, all weakly active computationally designed enzymes,79 
catalytic antibodies, or bovine serum albumin for that matter could be evolved in the 
laboratory to be highly efficient. Because we do not yet fully understand the features of an 
effective scaffold or starting point for the design or evolution of catalysis,80 we find it 
prudent to start with enzyme scaffolds that have proven ability to evolve (i.e. have diverged 
naturally to catalyze different reactions). Experience shows that enzymes like the 
cytochrome P450s or members of other functionally diverse superfamilies which have 
already diverged to catalyze many different reactions are also readily evolved in the 
laboratory, at least when the reactions share mechanistic features.81 This includes evolution 
of catalytic activities that have no natural counterpart, such as olefin cyclopropanation with 
diazo compounds or cyanation via epoxide opening. If one particular enzyme does not 
exhibit a desired promiscuous activity, other family members or even close variants may, as 
was shown for the MBL family21 and for the P450s.45
We can now begin to sketch out some general guidelines for engineering enzymes to 
catalyze reactions not known in nature: (1) For a given function, look for the most important 
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feature(s) that enables the transformation, e.g. iron-carbenoid for cyclopropanation, acid-
catalyzed formation of oxonium ion in the Prins reaction, or something as simple as the 
presence of a Michael acceptor for UAA synthesis; (2) Establish this feature or key 
intermediate in an enzyme based on known reactivity or mechanistic analogy, e.g. carbene is 
isoelectronic to oxene, a key intermediate in monooxygenation, or Brønsted acid activation 
is a key step in many terpene synthase cyclizations; (3) Evaluate variants of the enzyme or 
closely-related enzymes for the desired promiscuous activity; (4) Use directed evolution to 
improve the non-natural activity or tune selectivity. Computational approaches may be able 
to assist this discovery process, possibly in evaluating suitable enzyme starting points in 
silico.82
Of course, evolution and engineering of existing enzymes is not the only possible approach 
to creating new enzymes. There has been good progress with artificial metalloenzymes and 
de novo enzyme design, but significant challenges remain, especially for creating 
synthetically useful catalysts and ones that function inside of cells. This, we believe, is a key 
advantage of the evolutionary approach we review here: the starting point for creating a new 
enzyme is an existing enzyme that is functionally expressed in a microbial host and that can 
be improved by directed evolution, or at least by genetic modification. The ability to evolve 
the new function in the laboratory, starting from an already evolvable scaffold (an existing 
active site), greatly increases the chance that synthetically useful catalysts will emerge. The 
evolutionary approach we have described is limited to systems for which suitable starting 
enzymes exist. But where that is the case, progress to synthetically useful catalysts can be 
very rapid.33,47 For advances in the fields of artificial metalloenzymes and de novo enzyme 
design, we direct the readers to excellent reviews in refs 83 and 84.
Advances in mechanistic enzymology have allowed us to develop a greater understanding of 
the chemical basis of enzyme catalysis. This knowledge will help us select mechanisms and 
intermediates to ‘hijack’ for non-natural catalysis. Protein engineering and enzyme 
evolution, too, are progressing rapidly. Armed with these tools, we believe that exciting 
times are ahead for bridging the gap between nature’s chemical repertoire and the synthetic 
world.
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(A) Divergence of an ancestral enzyme having broad catalytic capabilities (denoted a, b, c, 
d, e) to more specialized enzymes (denoted A, B, C, D, E) that catalyze primarily one 
reaction; (B) Relationship between catalytic promiscuity and evolution of new function. A 
given protein sequence might catalyze multiple reactions. In the right circumstances, a 
catalyst with a low level of a promiscuous activity can be improved by mutation and natural 
(or artificial) selection so that it becomes specialized for a new function. For more 
discussion, see ref. 8.
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(A) Chlorohydrolase activity of AtzA and aminohydrolase activity of TriA; (B) TriA and 
AtzA (98% AA identity) are believed to be related through a common ancestor similar to 
TriA. These catalytic functions can be interconverted with a few amino acid mutations.13
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(A) Hydrolysis reactions catalyzed by PTE and lactonase; (B) Putative evolutionary 
relationship between lactonase and PTE and their interconversion in the laboratory.19,20
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Members of MBL superfamily are functionally highly interconnected, as illustrated by 
Tokuriki and co-workers.21 The different reactions catalyzed by members of the superfamily 
are connected to one another via promiscuous enzymes (gray circles) that catalyze two or 
more reactions. Figure is reproduced from reference 21.
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(A) Desaturation and hydroxylation reactions of oleic acid catalyzed by FAD2 (a desaturase) 
and LFAH12 (a hydroxylase); (B) Four mutations significantly increase hydroxylase activity 
of A. thaliana FAD2 desaturase, and a single mutation significantly increases desaturase 
activity of L. fendleri oleate hydroxylas\\e LFAH12.26,27
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(A) Promiscuous epoxide ring-opening activity of wild-type HHDH;32 (B) Application of 
HHDH in the synthesis of the atorvastatin side-chain and improvement of volumetric 
productivity using directed evolution.33
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(A) Mechanism of wild-type retaining β-glycosidase featuring catalytic acid/base and 
catalytic nucleophile residues where R′ = H or other sugar in low water concentration;38 (B) 
Engineered thioglycoligase via removal of catalytic acid/base residue, DNP = dinitrophenyl, 
Nuc = deoxythio sugar nucleophile as acceptor.35
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Use of engineered thioglycoligase for the synthesis of thiodisaccharides.35 Reported yields 
were after peracetylation of the thiodisaccharides. Wild-type enzymes do not catalyze this 
reaction.
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(A) Precedents of carbene and nitrene reactivity with iron porphyrins.40b,43 (B) Comparison 
of monooxygenation activity and non-natural carbene/nitrene transfer reactivity of P450-
BM3. Top box, reaction of Fe(III) of P450-BM3 with O2 and NAD(P)H generates 
compound I, the active species in monooxygenation. Bottom box, reaction of reduced Fe(II) 
with an activated species, followed by extrusion of N2 generates a putative carbenoid/
nitrenoid species.
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P450-catalyzed non-natural carbene and nitrene transfer reactions: (A) styrene 
cyclopropanation;44,46 (B) cyclopropanation of N,N-diethyl-2-phenylacrylamide en route to 
levomilnacipran;47 (C) N-H insertion reaction;49 (D) intramolecular C-H amination;50a,51 
(E) intermolecular sulfimidation;50b (F) regioselective C-H amination by different P450 
variants.50c
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Cyclization of squalene catalyzed by SHC and promiscuous activity of SHC on 
homofarnesol.54
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(A) SHC-catalyzed cyclization of terpene-like substrates, red color indicates bond(s) formed 
during the reaction;54–56 (B) SHC-catalyzed Prins cyclization of citronellal for production of 
isopulegol, a precursor to menthol, and activity improvement via mutation.57,58
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Cyclization reactions of various substrates utilizing functional group initiators such as 
epoxide and aldehyde with AacSHC and identification of enzyme variants with improved 
cyclization activities.59
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(A) Mechanisms of Fe/αKG hydroxylase (path a, in red) and Fe/αKG halogenase (path b, in 
blue) where a common reactive intermediate, A, is diverted into two reaction pathways 
depending on the ligand environment around the Fe center;62 (B) Divergent outcome of 
SyrB2-catalyzed reactions of threonine-SyrB1 and norvaline-SyrB1, indicating the complex 
interplay between the protein fold and substrate positioning in determining the outcome of 
SyrB2-catalyzed reaction.
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Use of O-acetylserine sulfhydrylase in the synthesis of unnatural β-substituted alanine 
derivatives and fermentation yields with E. coli strain W3110/pACcysEfbr.75
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Mechanism of tryptophan synthase and some representative UAAs prepared with wild-type 
tryptophan synthase.77,78
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